JPMorgan Chase & Co. Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

Replimune Group (NASDAQ:REPL) had its price objective boosted by JPMorgan Chase & Co. from $17.00 to $20.00 in a research report report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities research analysts also recently issued reports on the company. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target for the company in a research note on Tuesday, June 30th. Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Finally, Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.86.

Replimune Group Price Performance

NASDAQ REPL opened at $12.06 on Friday. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -3.57 and a beta of 0.88. Replimune Group has a 1-year low of $1.50 and a 1-year high of $13.90. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The business’s fifty day moving average price is $10.15 and its 200-day moving average price is $7.54.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, equities analysts predict that Replimune Group will post -2.54 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC bought a new position in shares of Replimune Group in the fourth quarter worth approximately $29,000. Russell Investments Group Ltd. raised its position in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares during the period. CWM LLC lifted its stake in shares of Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after buying an additional 2,886 shares in the last quarter. Essential Partners LLC lifted its stake in shares of Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after buying an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after buying an additional 6,873 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: The FDA granted accelerated approval to Tudriqev (RP1/vusolimogene oderparepvec) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed after an anti-PD-1-based treatment. The approval gives Replimune its first marketed product and creates a potential commercial revenue opportunity. Reuters FDA approval article
• Positive Sentiment: JPMorgan raised its price target on Replimune from $17 to $20 and maintained an “overweight” rating, indicating analysts see substantial upside from the company’s newly commercialized therapy. Benzinga price target report
• Positive Sentiment: Call-option activity was unusually high, with investors purchasing 25,580 calls—nearly double the average daily volume—suggesting increased speculative bullish positioning, although options activity does not guarantee further gains.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.